文献速递艾滋病与性传播感染

病毒学抑制的HIV感染者简化转换为双药治疗至第96周后的免疫与炎症变化:一项随机试验

Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial.
PubMed 文献 · Clin Microbiol Infect · 2022-03-11

这项开放标签、单中心随机对照试验纳入151例病毒学抑制的成人HIV感染者,随机分为继续三药治疗(TT)、转换为多替拉韦加拉米夫定(DTG/3TC)或达芦那韦/考比司他加拉米夫定(DRVc/3TC)。结果显示,三组在48周和96周的CD4+/CD8+比值变化、免疫激活与炎症指标、细胞相关HIV-DNA及未剪接HIV-RNA方面均相似。

要点

  • 在ITT和PP分析中,三组间免疫恢复情况相似。
  • 校正混杂因素后,CD4+/CD8+比值随时间的变化斜率与治疗分组无关(F=1.699;p=0.436),仅与基线值相关(F=756.871;p=0.000)。
  • 三组在免疫激活与炎症指标、CA-DNA和usRNA方面均无差异。

核心结论

  • 在病毒学抑制的HIV感染者中,无论是维持三药治疗还是简化转换为DTG/3TC或DRVc/3TC,三组间的免疫恢复、免疫激活与炎症、CA-DNA和usRNA均相似。

研究设计与样本

  • 开放标签、单中心、随机对照试验,纳入151例病毒学抑制的成人HIV感染者;14例患者未完成随访。

主要发现

  • ITT分析中,TT组、DTG/3TC组和DRVc/3TC组的CD4+/CD8+比值中位增幅在第48周分别为0.10、0.04和0.07,在第96周分别为0.09、0.05和0.08。
  • 校正混杂因素后,CD4+/CD8+比值随时间的变化斜率与治疗分组无关(F=1.699;p=0.436),仅与基线值相关(F=756.871;p=0.000)。
  • 三组在免疫激活与炎症指标、CA-DNA和usRNA方面均无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether simplification of antiretroviral treatment to dual therapy (DT) negatively impacts immune recovery (IR), immune activation and inflammation (IA/I), and HIV reservoir. METHODS: An open-label, single-centre, randomized controlled trial conducted in adult virologically suppressed HIV-infected patients on triple therapy (TT) with elvitegravir-cobicistat, emtricitabine and tenofovir alafenamide or dolutegravir (DTG), abacavir, and lamivudine (3TC). Participants were randomized to continue TT or switch to DTG, or darunavir/cobicistat (DRVc) plus 3TC. IR was assessed by CD4+/CD8+ ratio at 48 and 96 weeks. Changes in immune activation, proliferation, exhaustion, senescence, and apoptosis in CD4+ and CD8+ T cells, plasma sCD14, hsCRP, D-dimers, β2-microglobulin, IL-6, TNF-α and IP-10 levels, cell-associated HIV-DNA (CA-DNA), and unspliced HIV-RNA (usRNA) were also analysed. RESULTS: One hundred and fifty-one participants were enrolled. Fourteen patients did not complete the follow up. In the ITT and PP analysis, the IR was similar between the treatment arms. In the ITT analysis, the median increase in CD4+/CD8+ ratio was 0.10, 0.04, and 0.07 at week 48, and 0.09, 0.05, and 0.08 at week 96 for TT, DTG/3TC, and DRVc/3TC, respectively. After adjusting for confounding factors, the slopes of changes in CD4+/CD8+ ratio over time were independent of treatment (F = 1.699; p = 0.436) and related only to baseline values (F = 756.871; p = 0.000). There were no differences in IA/I, CA-DNA, or usRNA between treatment arms. DISCUSSION: Both IR and IA/I, CA-DNA, and usRNA were similar in the three treatment groups, regardless of maintaining TT or simplifying to DTG/3TC or DRVc/3TC in virologically suppressed HIV-infected patients.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Trujillo-Rodríguez M, Muñoz-Muela E, Serna-Gallego A, et al. Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. Clin Microbiol Infect. 2022. PMID: 35289296. doi:10.1016/j.cmi.2022.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。